National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Dupilumab (Dupixent®)

Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

NCPE Assessment Process Complete
Rapid review commissioned 13/11/2017
Rapid review completed 24/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by the HSE 29/11/2017
Pre-submission consultation with Applicant 18/06/2018
Submission received from Applicant 25/03/2019
Preliminary review sent to Applicant 05/06/2019
NCPE assessment re-commenced 01/07/2019
Factual accuracy sent to Applicant 08/11/2019
NCPE assessment re-commenced 22/11/2019
NCPE assessment completed 12/12/2019
NCPE assessment outcome The NCPE recommends that dupilumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*

 Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.